18 "Urinary Bladder" clinical trials found.
-
A Phase 1/2 First-in-Human Study of DCC-3116 as Monotherapy and in Combination with RAS/MAPK Pathway Inhibitors in Patients with Advanced or Metastatic Solid Tumors with RAS/MAPK Pathway Mutations
This study is designed for patients who have Advanced or Metastatic Solid Tumors with RAS/MAPK Pathway MutationsThe objective of the study is to ...
-
A Phase 1 Dose-escalation and Expansion Study of the PD-1 x ILT4 Bispecific Antibody CDX-585 in Patients with Advanced Malignancies
This is a study to test a new medicine called CDX-585 on patients with advanced or spreading solid tumors that have not improved with current ...
-
A Phase I First-in-human Open-label Multicenter Study to Investigate the Safety Tolerability Pharmacokinetics and Preliminary Antitumor Activity of SIM0237 in Adult Participants with Advanced Solid Tumors
This is a medical study for people with advanced solid tumors who haven't benefited from or can't have standard treatment. The study has ...
-
A phase 1/1b/2 study evaluating the safety tolerability pharmacokinetics pharmacodynamics and efficacy of AMG 193 alone and in combination with docetaxel in subjects with advanced MTAP-null solid tumors
This study is for adults who have advanced solid tumors that lack a certain enzyme called methylthioadenosine phosphorylase (MTAP). This study is split into two ...
-
A PHASE 1 STUDY OF TJ033721 IN SUBJECTS WITH ADVANCED OR METASTATIC SOLID TUMORS.
You can participate in this study if you are diagnosed with advanced solid tumors. The purpose of this study is to test the safety of ... -
A Phase 2b Randomized Double-blind Placebo-controlled Multi-center study of the Effects of Psilocybin-assisted Psychotherapy on Psychiatric and Existential Distress in Advanced Cancer
The purpose of this research is to study the safety and effects of single-dose psilocybin 25mg versus an active placebo (single dose niacin 100mg) in ... -
A PHASE 3 RANDOMIZED PLACEBO-CONTROLLED DOUBLE-BLIND MULTICENTER TRIAL OF SELINEXOR IN MAINTENANCE THERAPY AFTER SYSTEMIC THERAPY FOR PATIENTS WITH P53 WILD-TYPE ADVANCED OR RECURRENT ENDOMETRIAL CARCINOMA
This is a study to test a drug called selinexor for patients with EC (endometrial carcinoma). The drug will be given to patients who have ...
-
A Phase 1b Study of Nivolumab in Patients with Autoimmune Disorders and Advanced Malignancies (AIM-NIVO)
We want to know the safety and tolerability of the anti-programmed death 1 (PD-1) antibody nivolumab at different dose levels for patients with autoimmune disorders ...